INTRODUCTION
Kininogens are plasma proteins which are the natural substrates of plasma and tissue kallikrein and yield, on hydrolysis, the nonapeptide, bradykinin. In 1967, two forms of purified human plasma kininogen (kinin precursors) were described by Jacobsen and Kriz: (ref 
GENETICS OF HIGH MOLECULAR WEIGHT KlNlNOGEN
Both HK and LK are coded for by the same single copy gene (ref. 5). The gene is 27 kb long and consists of 11 exons in which the primary transcripts are differentally spliced to yield two different RNAs. Low molecular weight kininogen contains the first 9 exons plus a small part of the 10th including the codons for bradykinin and 12 additional amino acids. It is then spliced to the 11th exon. HK contains the same 9 exons plus all of the long 10th exon. After translation and removal of the signal peptide and glycosylation of about 40% by weight, HK has a molecular weight of 120 kDa and LK of 68 kDa.
We localized the gene by in situ hybridization of a metaphase chromosome spread to chromosome 3q26q to terminal (ref. 6) . Nearby are the genes for the evolutionarily related cystatins, histidine-rich glycoprotein and a2HS glycoprotein.
We have also recently characterized the mutation in Ms. Williams, who lacked both HK and LK (ref.7) . Northern analysis, reverse transcriptase and PCR showed a normal pattern of the two mRNAs present in her post mortem liver, and Southern analysis failed to show a gross defect with 20 restriction enzymes. Primers flanking each exon were used for PCR amplification of normal and Williams gene. Each amplified exon fragment was sequenced. A C to T transition was located at nucleotide 587 downstream from the start codon ATG, resulting in a CGA (Arg)-TGA (stop) mutation in exon 5 of the kininogen gene. Since the stop mutation is localized before the differential splice site (in exon lo), the synthesis of both LK and HK proteins are affected.
The mutation eliminates the recognition site of the restriction enzyme Csp45-I. Results of Csp45-I enzyme digestion of the PCR amplified exon 5 fragments (252 bp) of the patient, 3 daughters (with 50% functional HK), and 1 granddaughter (normal functional HK) reveal that the patient is homozygous (1 band: 252 bp) for the mutation, while the 3 daughters are heterozygous (3 bands: 252, 134 and 118 bp). The coagulant activities confirm that the inheritance is autosomal recessive. This family represents the first documented mutation defined as responsible for total kininogen deficiency.
D O M A I N STRUCTURE OF HIGH MOLECULAR WEIGHT KlNlNOGEN
The mature form of HK protein contains 626 amino acids (Fig. 1) . On cleavage by kallikrein, the nonapeptide bradykinin is released from D4 corresponding to the beginning of the 10th exon. The cleaved protein contains an NH2-terminal heavy chain (362 amino acids) bound to a COOH-terminal light chain (255 amino acids) by a single interchain disulfide bridge. The heavy chain consists of three large domains, D1, D2, D3, each derived evolutionarily from the more primitive cystatin by gene duplication and corresponding to the first 9 exons, and is identical in HK and LK. LK has a unique small (4 kDa) light chain of unknown function. The light chain of HK (56 kDa) contains the procoagulant activity which depends in part on its ability to associate with the zymogens, prekallikrein (PK), (ref. 8) through residues 556 to 595 of HK, or FXI, through residues 556-613 (D6). The coagulant activity of HK also depends on the binding of cleaved HK to hydrophilic surfaces. This function is thought to be mediated through its histidine-glycine-rich region (residues 407-498) (D5).
PROTEOLYTIC CLEAVAGE OF HIGH MOLECULAR WEIGHT KlNlNOGEN
Plasma kallikrein cleaves HK in a three-step sequential manner (ref. 
SURFACE BINDING DOMAIN OF HIGH MOLECULAR WEIGHT KlNlNOGEN
To obtain additional data regarding the composition of the surface binding site of HK (D5), we further characterized MAb C11C1, an antibody developed in our laboratory, (ref. 13) which recognizes specifically the light chain of HK and inhibits coagulant activity. We found that an IgG fraction of MAb CllCl inhibited the binding of lZI-HK to an anionic surface, kaolin, 57% at a final concentration of 30 mM. Furthermore, this was specific since the MAb 2B5 to the heavy chain failed to inhibit the coagulant activity. This finding confirms that the light chain is responsible for the coagulant activity. The action of MAb CllCl is selective since there was no interference with %FXI binding to HK and no changes in the rate of cleavage of HK by plasma kallikrein.
Since MAb CllCl selectively inhibited the binding of HK to kaolin, we then defined the epitope in native HK light chain ( Fig. 2 ) which was recognized (ref. 14). When HK (lane 1) was digested sequentially with plasma kallikrein and factor XIa, a series of polypeptides resulted including the largely intact heavy chain is seen along with a small amount of undigested light chain (1) as well as main fragments 11 and 12. Purification by affinity chromatography on MAb CllCl bound to agarose followed by molecular filtration yielded 4 a polypeptide of 7.3 m a .
When the peptide was subjected to amino acid analysis, it proved to be composed of predominantly His and Gly. Moreover, the peptide did not adsorb to the Immobilon-P-membrane normally used for sequencing. Therefore, it was covalently coupled to aminophenyl-glass fiber paper to obtain the N-terminal sequence. The first 6 amino acids were HGLGHG; however, despite an adequate yield, no sequence was obtained from steps 7 through 17. Since the covalent coupling is to free COOH groups, the presence of a Glu in position 8 would prevent the further sequencing since it would be the part of the covalent attachment. Based on the Mr and the N-terminal analysis, the sequence was determined as 459-516 and did not overlap with the sequence 556-613 responsible for binding FXI.
To further define the requirements for interaction of human HK with negatively-charged surfaces, we selected and synthesized HGLGHGH because it is a highly conserved sequence found in human as well as in bovine HK, and because it forms the N-terminal amino acid sequence of the 7.3 kDa peptide containing 57 amino acids. HGLGHGH is repeated twice (residues 441-447 and 451-457) within the second of the three homologous regions.
We then investigated the effect of HGLGHGH and two unrelated control peptides (RGYSLG and HHLGGHKQAGDV) upon the binding of cleaved ' "I-HK to kaolin (Fig. 3) . At a concentration of 5000 pM, HGLGHGH blocked the specific binding of ' "I-HK to kaolin 50%. The control peptides had no effect. Each-value is the mean of duplicate assays. Reproduced with permission from reference 14.
We therefore synthesized another peptide of intermediate length -a heptadecapeptide. The feature of this peptide derived from the light chain of HK is that the heptapeptide is repeated twice with a glutamic acid-glutamine-glutamine sequence intervening. The HEQQH is a canonic sequence similar to that of thermolysin for zinc binding. This 17-mer inhibited the binding of '%HK to kaolin 50% at 2300 pM but in the presence of zinc this declined to 630 pM. The 73 kDa peptide, 1% inhibited at 380 pM.
Thus, we have defined a heptadecapeptide which binds zinc and comprises much of the surface binding domain of HK. However, additional residues contained in a 57 amino acid sequence may also comprise areas important for interaction with anionic surfaces.
We then examined the surface binding domain amino acids more closely (Fig. 4) . When this sequence is compared to bovine and rat, we find significant sequence homologies. The residues 443-475 HG-rich region is 55% homologous and especially in the heptadecapeptide region. After an area of lower homology missing in the bovine protein, a second area rich in HG and lysine (K) is 61% homologous. We therefore designed deletion mutants to examine both of these regions as well as the domain 6 region which binds factor XI and prekallikrein. have generated various deletion mutants of HK LC and the stuctures of these recombinant -fragments expressed in E. coli (Fig. 5) . All the recombinant fragments contain glutathione S-transferase (GST) at their N-terminus. The rHK LC contains residues Lys438-Ser644 of HK comprising the HG-rich region, HGK-rich region, and domain 6 (the zymogen binding region). The deletion mutants His459-Ser644, Glu466-Ser644, Leu-483-Ser644, and His 493-Ser644 lack residues 438-458,438-465,438-482, and 438-492 (in the HK-rich region), respectively, but contain domain 6 at the C-terminus. The fragment His493-Ser644 thus contains HGK-rich region, domain 6, but not HG-rich region. The recombinant fragment Ser583-Ser644 lacks residues 438-582 (entire domain 5 and part of domain 6). The recombinant fragment Lys438-Asp492 contains HK-rich region but lacks HGK-rich region and domain 6, while the fragment Lys438-Ser531 contains both HG-rich and HGK-rich regions (entire domain 5), and lacks entire domain 6. The deletion mutant D493-520 HK LC contains HG-rich region and entire domain 6, and lacks HGK-rich region. Each mutant was tested for its ability to inhibit the binding of ' %HK (Table I) In order to further examine the results obtained by competition experiments, two recom inant fragments lacking the C-terminus of HK LC (Lys438-Asp492 and Lys438-Ser531) were produced. The fragments His493-Ser644, Lys438-Ser53 1, and Ser583-Ser644 were radiolabeled by Iodogen method. In order to rule out the presence of a surface binding subdomain in residues N-terminal to 493-His, recombinant fragment Lys438-Asp492 was also radiolabeled. These fragments were then used in a kaolin binding assay. Radiolabeled HK LC and fragment Lys438-Ser531 and His493-Ser644 bound to kaolin, displacing fibrinogen in a concentration-dependent manner, indicating that the surface binding components are present on these proteins. The Ser583-Ser644 fragment, lacking the entire domain 5, did not bind to kaolin in a concentration-dependent manner, indicating the deficiency of a surface binding component. Consistent with our peptide data, Lys438-Asp492 fragment also bound to kaolin in a concentration-dependent manner. This result confirmed the presence of a second anionic surface binding subdomain in the HG-rich region (Lys438-Asp492) of HK LC.
In order to determine the specificity of radiolabeled recombinant fragment binding to kaolin, unlabeled HKa was included in the assay at increasing molar ratios. Except for the Ser583-Ser644 fragment, all the radiolabeled recombinant fragments were displaced by unlabeled HKa, indicating that the binding of these fragments to kaolin is specific and that they all contain at least one anionic surface binding subdomain. The presence of more than one subdomain does not seem to increase the binding either additively or synergistically (Lys438-Ser53 1 fragment and rHK LC). The binding of Ser583-Ser644 fragment was low and nonspecific, and hence was not displaced with unlabeled HKa. These results are in agreement with the direct binding studies.
If there were two subdomains in domain 5 of HK LC, then the presence of either surface binding subdomain and zymogen binding region in any HK LC recombinant fragment could result in coagulant activity. This possibility was tested by constructing a deletion mutant of HK LC lacking residues 493-520 (HGK-rich region). Thus, if there is a surface binding subdomain in the HG-rich region (Lys438-Asp492) of HK LC, then this fragment lacking residues 493-520 should have coagulant activity. Similarly, the His493-Ser644 fragment should have coagulant activity if residues 493-520 (HGK-rich region) contain a surface binding subdomain. The coagulant activity of various recombinant fragments was assayed (Table 11) . As shown, rHK LC, His493-Ser644 fragment and D493-520 HK LC have similar coagulant specific activities, while the other HK LC fragments Lys438-Asp492, Lys438-Ser531, and Ser583-Ser644 did not have clotting activity. The coagulant activity is a result of HK LC binding both to anionic surfaces and the zymogens. Fragments Lys438-Asp492 and Lys438-Ser531 have only one or both anionic surface binding subdomains but not the zymogen binding region, while the Ser583-Ser644 fragment contains only zymogen binding subdomain. The recombinant fragment D493-520 HK LC contains Lys438-Asp492 (HG-rich surface binding subdomain) fused to Thr521-Ser644 (zymogen binding subdomain) and hence has coagulant activity, while the surface binding HGK-rich subdomain C-terminus to 493-His is responsible for coagulant activity of the His493-Ser644 fragment.
These results confirm the presence of two anionic surface binding subdomains, one in the HG-rich region and the other in the HGK-rich region in HK LC.
HK-A CYSTEINE PROTEASE INHIBITOR
We will now focus on the heavy chain of HK. The heavy chain consists of three large domains, D1, D2, and D3, each derived evolutionarily from the more primitive cystatin by gene duplication and corresponding to the first 9 exons, and is identical in HK and low molecular weight kininogen (LK). Domains 2 and 3 both inhibit papain and have the conserved Q W A G motif. We demonstrated that the platelet calcium-activated thiol protease, calpain, was potently inhibited by human HK and less so by LK and aZmacroglobulin (ref. 15) . In a detailed investigation of the kinetics of the inhibition, we demonstrated that HK was a tight binding inhibitor with a Ki of 500 pM (ref. 16 ). This implied a close fit between HK and platelet calpain. Only domain 2 inhibits calpain.
We therefore turned to the importance of specific amino acids in the HK heavy chain for the inhibition of platelet calpain. The sequence Q W A G (Gln-Val-Val-Ala-Gly) in the heavy chain of kininogen is thought to be important in its inhibitory action. Moreover, the addition of the nitrosulfopyridyl ring results in an adduct perpendicular to the rest of the structure in possible position to react with the active site of calpain.
Therefore, a series of peptides was synthesized by Dr. Rei Matsueda which have this sequence with Cys substituted for alanine and nitrosulfopyridine linked to the sulfhydryl group (ref. 17) . This activated SH group can react covalently with the SH group at the active site of calpain. Although Q W A G itself is not inhibitory, these peptides proved to be a potent affinity label or irreversible inhibitor of calpain. Presumably, Q W A G provided a binding region and the nitrosulfopyridine could react with the SH in the active site. The most specific turned out to be P1, FQWC(PyS)G. (ref. 19 ).
When P1 is in molar excess to calpain, the reaction obeys pseudo-first order kinetics. When the rate constant is plotted as a function of inhibitor concentration, the slope is the second order rate constant, about 6 x 1dM's-l.
We are currently modeling D2, which inhibits calpain, to find inhibitory sites other than QWAG.
